The number of Xarelto cases filed in court against the makers of popular blood thinning drug Xarelto continues to grow, as do the drug’s sales. Despite the mounting number of lawsuits against Bayer and Johnson & Johnson’s Janssen Pharmaceuticals, Xarelto remains the most popular anticoagulant in the United States. EvaluatePharma also reports that the drug will remain on top in Europe through the year 2022.
According to Drug Watch there were 5260 claims pending in federal court where plaintiffs allege strokes, hemorrhages and blood clots were caused by Bayer’s drug. From the 5000+ cases, 40 were pooled into preliminary bellwether trials which will being in early 2017. These initial trials will likely predict how the rest of the cases will play out.
Some attorneys are claiming that, though still early, it’s possible these cases will be similar to the earlier Pradaxa claims. The manufacturer of Pradaxa, another blood thinner, settles in 2014 for $650 million. Lawyers involved in the Xarelto lawsuits also think the number of cases will continue to increase as media attention continues to grow.